{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:52:49Z","timestamp":1789876369697,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["211153\/Z\/18\/Z"],"award-info":[{"award-number":["211153\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is growing evidence that antibody responses play a role in the resolution of SARS-CoV-2 infection. Patients with primary or secondary antibody deficiency are at increased risk of persistent infection. This challenging clinical scenario is associated with adverse patient outcome and potentially creates an ecological niche for the evolution of novel SARS-CoV-2 variants with immune evasion capacity. Case reports and\/or series have implied a therapeutic role for convalescent plasma (CP) to secure virological clearance, although concerns have been raised about the effectiveness of CP and its potential to drive viral evolution, and it has largely been withdrawn from clinical use in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report two cases in which persistent SARS-CoV-2 infection was cleared following administration of the monoclonal antibody combination casirivimab and imdevimab (REGN-COV2, Ronapreve). A 55-year-old male with follicular lymphoma, treated with B cell depleting therapy, developed SARS-CoV-2 infection in September 2020 which then persisted for over 200\u00a0days. He was hospitalised on four occasions with COVID-19 and suffered debilitating fatigue and malaise throughout. There was no clinical response to antiviral therapy with remdesivir or CP, and SARS-CoV-2 was consistently detected in nasopharyngeal swabs. Intrahost evolution of several spike variants of uncertain significance was identified by viral sequence analysis. Delivery of REGN-COV2, in combination with remdesivir, was associated with clinical improvement and viral clearance within 6\u00a0days, which was sustained for over 150\u00a0days despite immunotherapy for relapsed follicular lymphoma. The second case, a 68-year-old female with chronic lymphocytic leukaemia on ibrutinib, also developed persistent SARS-CoV-2 infection. Despite a lack of response to remdesivir, infection promptly cleared following REGN-COV2 in combination with remdesivir, accompanied by resolution of inflammation and full clinical recovery that has been maintained for over 290\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These cases highlight the potential benefit of REGN-COV2 as therapy for persistent SARS-CoV-2 infection in antibody deficient individuals, including after failure of CP treatment. Formal clinical studies are warranted to assess the effectiveness of REGN-COV2 in antibody-deficient patients, especially in light of the emergence of variants of concern, such as Omicron, that appear to evade REGN-COV2 neutralisation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12941-021-00491-2","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T08:02:48Z","timestamp":1640851368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Yusri","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Wardle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirelle","family":"Burton-Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias L.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-2315","authenticated-orcid":false,"given":"Christopher J. A.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"issue":"10283","key":"491_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459\u201369.","journal-title":"Lancet"},{"issue":"4","key":"491_CR2","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jinf.2020.12.023","volume":"82","author":"AT Hanrath","year":"2021","unstructured":"Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J Infect. 2021;82(4):e29\u201330.","journal-title":"J Infect"},{"issue":"6","key":"491_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2034545","volume":"384","author":"SF Lumley","year":"2021","unstructured":"Lumley SF, O\u2019Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533\u201340.","journal-title":"N Engl J Med"},{"issue":"27","key":"491_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"491_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"13","key":"491_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021;385(13):1172\u201383.","journal-title":"N Engl J Med"},{"issue":"10269","key":"491_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"issue":"7","key":"491_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","volume":"27","author":"F Krammer","year":"2021","unstructured":"Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021;27(7):1147\u20138.","journal-title":"Nat Med"},{"key":"491_CR9","doi-asserted-by":"crossref","unstructured":"Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021.","DOI":"10.1101\/2021.06.21.21258528"},{"issue":"32","key":"491_CR10","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423\u20138.","journal-title":"Vaccine"},{"issue":"7","key":"491_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"7","key":"491_CR12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","volume":"183","author":"VA Avanzato","year":"2020","unstructured":"Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901\u201312.","journal-title":"Cell."},{"issue":"1","key":"491_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","volume":"223","author":"JH Baang","year":"2021","unstructured":"Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23\u20137.","journal-title":"J Infect Dis"},{"issue":"1","key":"491_CR14","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","volume":"11","author":"MS Buckland","year":"2020","unstructured":"Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020;11(1):6385.","journal-title":"Nat Commun"},{"issue":"4","key":"491_CR15","first-page":"e0048021","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH, et al. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Sphere. 2021;6(4):e0048021.","journal-title":"Sphere."},{"issue":"1","key":"491_CR16","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.xcrm.2020.100164","volume":"2","author":"K Honjo","year":"2021","unstructured":"Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, et al. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Rep Med. 2021;2(1):100164.","journal-title":"Cell Rep Med."},{"issue":"20","key":"491_CR17","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","volume":"136","author":"T Hueso","year":"2020","unstructured":"Hueso T, Pouderoux C, Pere H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290\u20135.","journal-title":"Blood"},{"issue":"10","key":"491_CR18","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.jaip.2020.08.059","volume":"8","author":"H Jin","year":"2020","unstructured":"Jin H, Reed JC, Liu STH, Ho HE, Lopes JP, Ramsey NB, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(10):3594\u20136.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"7853","key":"491_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277\u201382.","journal-title":"Nature"},{"issue":"19","key":"491_CR20","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1182\/bloodadvances.2020002595","volume":"4","author":"T Luetkens","year":"2020","unstructured":"Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, et al. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv. 2020;4(19):4864\u20138.","journal-title":"Blood Adv"},{"key":"491_CR21","doi-asserted-by":"crossref","unstructured":"Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis. 2020.","DOI":"10.1093\/cid\/ciaa1637"},{"issue":"8","key":"491_CR22","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.jaip.2020.06.046","volume":"8","author":"E Mira","year":"2020","unstructured":"Mira E, Yarce OA, Ortega C, Fernandez S, Pascual NM, Gomez C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract. 2020;8(8):2793\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"491_CR23","doi-asserted-by":"publisher","first-page":"100089","DOI":"10.1016\/j.clinpr.2021.100089","volume":"12","author":"H Nguyen","year":"2021","unstructured":"Nguyen H, Salkeld J, Agarwal S, Goodman A. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. Clin Infect Pract. 2021;12:100089.","journal-title":"Clin Infect Pract."},{"issue":"8","key":"491_CR24","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/trf.16525","volume":"61","author":"JW Senefeld","year":"2021","unstructured":"Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021;61(8):2503\u201311.","journal-title":"Transfusion"},{"issue":"9","key":"491_CR25","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/infdis\/jiab075","volume":"223","author":"H Tarhini","year":"2021","unstructured":"Tarhini H, Recoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P, et al. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. J Infect Dis. 2021;223(9):1522\u20137.","journal-title":"J Infect Dis"},{"key":"491_CR26","doi-asserted-by":"publisher","first-page":"103355","DOI":"10.1016\/j.ebiom.2021.103355","volume":"67","author":"TT Truong","year":"2021","unstructured":"Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. EBioMedicine. 2021;67:103355.","journal-title":"EBioMedicine."},{"issue":"8","key":"491_CR27","doi-asserted-by":"publisher","first-page":"ofab335","DOI":"10.1093\/ofid\/ofab335","volume":"8","author":"P Luitel","year":"2021","unstructured":"Luitel P, Vais D, Gidron A. Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report. Open Forum Infect Dis. 2021;8(8):ofab335.","journal-title":"Open Forum Infect Dis."},{"key":"491_CR28","doi-asserted-by":"crossref","unstructured":"Kavanagh Williamson M, Hamilton F, Hutchings S, Pymont HM, Hackett M, Arnold D, et al. Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual. MedRxiv. 2021.","DOI":"10.1101\/2021.05.31.21257591"},{"issue":"10","key":"491_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S1473-3099(21)00464-3","volume":"21","author":"E Moran","year":"2021","unstructured":"Moran E, Cook T, Goodman AL, Gupta RK, Jolles S, Menon DK, et al. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect Dis. 2021;21(10):1345\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"491_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382\u201393.","journal-title":"Nat Rev Immunol"},{"issue":"10289","key":"491_CR31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"Group RC","year":"2021","unstructured":"Group RC. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049\u201359.","journal-title":"Lancet"},{"issue":"3","key":"491_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238\u201351.","journal-title":"N Engl J Med"},{"key":"491_CR33","doi-asserted-by":"crossref","unstructured":"Rocco PRM, Silva PL, Cruz FF, Melo-Junior MAC, Tierno P, Moura MA, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021;58:1.","DOI":"10.1183\/13993003.03725-2020"},{"key":"491_CR34","doi-asserted-by":"crossref","unstructured":"Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2021.","DOI":"10.1016\/j.jaci.2021.10.031"},{"key":"491_CR35","doi-asserted-by":"crossref","unstructured":"Shields AM, Burns SO, Savic S, Richter AG, Consortium UPC-. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin Immunol. 2021;147(3):870\u20135 e1.","DOI":"10.1016\/j.jaci.2020.12.620"},{"issue":"23","key":"491_CR36","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383(23):2291\u20133.","journal-title":"N Engl J Med"},{"key":"491_CR37","doi-asserted-by":"crossref","unstructured":"Rodionov RN, Biener A, Spieth P, Achleitner M, Holig K, Aringer M, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe. 2021;2(4):e138.","DOI":"10.1016\/S2666-5247(21)00030-6"},{"issue":"6534","key":"491_CR38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.abf6950","volume":"371","author":"KR McCarthy","year":"2021","unstructured":"McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371(6534):1139\u201342.","journal-title":"Science"},{"key":"491_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijid.2020.12.050","volume":"104","author":"D Camprubi","year":"2021","unstructured":"Camprubi D, Gaya A, Marcos MA, Marti-Soler H, Soriano A, Mosquera MDM, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379\u201381.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"491_CR40","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C, et al. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. J Infect Dis. 2020;222(7):1103\u20137.","journal-title":"J Infect Dis"},{"key":"491_CR41","doi-asserted-by":"crossref","unstructured":"Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C, et al. Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis. 2021.","DOI":"10.1016\/j.ijid.2021.11.040"},{"key":"491_CR42","doi-asserted-by":"crossref","unstructured":"Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020.","DOI":"10.1101\/2020.06.22.20137273"},{"issue":"10285","key":"491_CR43","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"Group RC","year":"2021","unstructured":"Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345.","journal-title":"Lancet"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-021-00491-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-021-00491-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-021-00491-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T08:04:49Z","timestamp":1640851489000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-021-00491-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1186\/s12941-021-00491-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-991639\/v1","asserted-by":"object"}]},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable to this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients provided written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WO declares funding from Roche. The remaining authors declare no competing financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}